{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:25Z","timestamp":1791924205889,"version":"4.3.4"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chronic kidney disease is common in patients with multiple myeloma. Historically, individuals with end-stage renal disease and multiple myeloma did poorly with renal transplantation due to higher mortality rates from the malignancy itself or associated comorbidities. However, over the past 2 decades, there have been significant advances in the treatment of multiple myeloma with the advent of new therapeutic agents resulting in an improvement of long-term survival. As a result, more individuals with multiple myeloma are being referred for kidney transplantation, especially those with good functional capacity and minimal comorbidities. Recent literature has suggested that certain patients with multiple myeloma can successfully undergo renal transplantation after stem transplantation with consideration for maintenance therapy, although caution should be used with immunomodulating drugs due to the anecdotally reported risk of acute rejection. Therefore, having a multidisciplinary approach with the transplant team and hematology both before and after transplant is crucial in maximizing the chance of success for these individuals. This review summarizes the literature on renal transplantation in patients with multiple myeloma as well as the therapeutic advancements that have occurred which may allow certain patients to undergo successful transplantation.<\/jats:p>","DOI":"10.1097\/tp.0000000000002449","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T07:06:42Z","timestamp":1538204802000},"page":"1994-2001","source":"Crossref","is-referenced-by-count":24,"title":["Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma"],"prefix":"10.1097","volume":"102","author":[{"given":"Janna L.","family":"Huskey","sequence":"first","affiliation":[{"name":"Department of Medicine, Mayo Clinic, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Heilman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Khamash","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20231002","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2215\/CJN.12231212","article-title":"Kidney disease and multiple myeloma","volume":"8","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"bib2-20231002","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/ndt\/gfp679","article-title":"Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA registry study","volume":"25","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"bib3-20231002","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.06290615","article-title":"Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis","volume":"11","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"bib4-20231002","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","year":"2017","journal-title":"Leukemia"},{"key":"bib5-20231002","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus Melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' collaborative group","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"bib6-20231002","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib7-20231002","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"bib8-20231002","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"bib9-20231002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib10-20231002","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","year":"2007","journal-title":"Blood"},{"key":"bib11-20231002","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib12-20231002","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","year":"2007","journal-title":"Blood"},{"key":"bib13-20231002","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1517\/14656566.5.6.1321","article-title":"A review of the proteasome inhibitor bortezomib in multiple myeloma","volume":"5","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"bib14-20231002","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","year":"1999","journal-title":"N Engl J Med"},{"key":"bib15-20231002","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"bib16-20231002","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","article-title":"Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"key":"bib17-20231002","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","year":"2017","journal-title":"Lancet Haematol"},{"key":"bib18-20231002","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1080\/14656566.2017.1409207","article-title":"Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against","volume":"18","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"bib19-20231002","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib20-20231002","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14712598.2016.1221920","article-title":"Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma","volume":"16","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"bib21-20231002","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7326\/0003-4819-83-5-651","article-title":"Renal transplantation in multiple myeloma. A case report","volume":"83","year":"1975","journal-title":"Ann Intern Med"},{"key":"bib22-20231002","first-page":"206","article-title":"Severe renal failure in multiple myeloma","volume":"15","year":"1981","journal-title":"Clin Nephrol"},{"key":"bib23-20231002","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00007890-198103000-00016","article-title":"Kidney transplant in multiple myeloma. Early recurrence in the graft with sustained normal renal function","volume":"31","year":"1981","journal-title":"Transplantation"},{"key":"bib24-20231002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000166684","article-title":"Renal transplantation in light-chain multiple myeloma","volume":"3","year":"1983","journal-title":"Am J Nephrol"},{"key":"bib25-20231002","first-page":"903","article-title":"Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment","volume":"73","year":"1989","journal-title":"Q J Med"},{"key":"bib26-20231002","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/00007890-199612150-00008","article-title":"Renal transplantation in multiple myeloma. Case report and review of the literature","volume":"62","year":"1996","journal-title":"Transplantation"},{"key":"bib27-20231002","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/ndt\/11.7.1486","article-title":"Multiple myeloma treatment in dialysis-dependent patients: to transplant or not to transplant?","volume":"11","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"bib28-20231002","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1097\/TXD.0000000000000716","article-title":"Kidney transplantation in patients with active multiple myeloma: case reports","volume":"3","year":"2017","journal-title":"Transplant Direct"},{"key":"bib29-20231002","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/TP.0b013e31820a3068","article-title":"Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease","volume":"91","year":"2011","journal-title":"Transplantation"},{"key":"bib30-20231002","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1016\/j.transproceed.2013.10.005","article-title":"Successful treatment of renal failure caused by multiple myeloma with HLA-identical living kidney and bone marrow transplantation: a case report","volume":"45","year":"2013","journal-title":"Transplant Proc"},{"key":"bib31-20231002","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1111\/j.1600-6143.2006.01434.x","article-title":"Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses","volume":"6","year":"2006","journal-title":"Am J Transplant"},{"key":"bib32-20231002","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/00007890-200211270-00011","article-title":"Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease","volume":"74","year":"2002","journal-title":"Transplantation"},{"key":"bib33-20231002","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3727\/096368915X688560","article-title":"Hematopoietic cell and renal transplantation in plasma cell dyscrasia patients","volume":"25","year":"2016","journal-title":"Cell Transplant"},{"key":"bib34-20231002","article-title":"Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor\u2014a multicenter analysis","journal-title":"Am J Transplant"},{"key":"bib35-20231002","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1523-1755.2004.00427.x","article-title":"High dose chemotherapy in light chain or light and heavy chain deposition disease","volume":"65","year":"2004","journal-title":"Kidney Int"},{"key":"bib36-20231002","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1093\/ndt\/gfl403","article-title":"A case of successful double sequential bone marrow and kidney transplantations in a patient with multiple myeloma","volume":"21","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"bib37-20231002","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/bmt.2008.179","article-title":"High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease","volume":"42","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"bib38-20231002","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/ndt\/gfm918","article-title":"Long-term outcome of autologous stem cell transplantation in light chain deposition disease","volume":"23","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"bib39-20231002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/bmt.2010.82","article-title":"Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation","volume":"46","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"bib40-20231002","first-page":"1","article-title":"Safety and efficacy of high dose melphalan and autologous stem cell transplantation prior to renal allograft in end-stage renal failure secondary to monoclonal immunoglobulin deposition disease","volume":"3","year":"2011","journal-title":"Cellular Therapy and Transplantation"},{"key":"bib41-20231002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/nep.12116","article-title":"Renal transplant in plasma cell dyscrasias with lenalidomide treatment after autologous stem cell transplantation","volume":"18","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"bib42-20231002","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1053\/j.ajkd.2016.12.023","article-title":"Kidney transplantation for kidney failure due to multiple myeloma: case reports","volume":"69","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"bib43-20231002","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMct0805626","article-title":"Autologous hematopoietic stem-cell transplantation for multiple myeloma","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"bib44-20231002","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2016.11.024","article-title":"Acute kidney allograft rejection precipitated by lenalidomide treatment for multiple myeloma","volume":"69","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"bib45-20231002","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/ajt.12391","article-title":"Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"key":"bib46-20231002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1526924816679842","article-title":"Treatment of multiple myeloma in a heart transplant recipient","volume":"27","year":"2017","journal-title":"Prog Transplant"},{"key":"bib47-20231002","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","year":"2006","journal-title":"Blood"},{"key":"bib48-20231002","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood-2012-06-435503","article-title":"Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma","volume":"121","year":"2013","journal-title":"Blood"},{"key":"bib49-20231002","doi-asserted-by":"crossref","first-page":"24031","DOI":"10.18632\/oncotarget.15234","article-title":"Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib50-20231002","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"bib51-20231002","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1158\/1078-0432.CCR-07-0527","article-title":"Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling","volume":"13","year":"2007","journal-title":"Clin Cancer Res"},{"key":"bib52-20231002","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"bib53-20231002","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib54-20231002","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","year":"2017","journal-title":"Blood"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007890-201812000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:26:51Z","timestamp":1696224411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201812000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002449","relation":{},"ISSN":["1534-6080","0041-1337"],"issn-type":[{"value":"1534-6080","type":"electronic"},{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}